[DISCLOSURE] Celltrion (068270) announced on Sept. 25 that it has signed a 77.0 billion won (US$68.0 million) contract with its affiliate Celltrion Healthcare (091990) to supply biosimilar antibody Truxima. 

This amounts to 11.48 percent of its 2016 revenue and the contract is valid until Sept. 30.

By Hwang You-mee (glamazon@heraldcorp.com)